Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer
- PMID: 25993269
- DOI: 10.1021/acs.jmedchem.5b00099
Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer
Abstract
A strategy to develop chemotherapeutic agents by combining several active groups into a single molecule as a conjugate that can modulate multiple cellular pathways may produce compounds having higher efficacy compared to that of single-target drugs. In this article, we describe the synthesis and evaluation of an array of dual-acting ER and histone deacetylase inhibitors. These novel hybrid compounds combine an indirect antagonism structure motif of ER (OBHS, oxabicycloheptene sulfonate) with the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA). These OBHS-HDACi conjugates exhibited good ER binding affinity and excellent ERα antagonistic activity, and they also exhibited potent inhibitory activities against HDACs. Compared with the approved drug tamoxifen, these conjugates exhibited higher antitumor potency in ERα-positive breast cancer cells (MCF-7). Moreover, these conjugates not only showed selective anticancer activity that was more potent against MCF-7 cells than DU 145 (prostate cancer), but they had no toxicity toward normal cells.
Similar articles
-
Novel hybrid conjugates with dual estrogen receptor α degradation and histone deacetylase inhibitory activities for breast cancer therapy.Bioorg Med Chem. 2021 Jun 15;40:116185. doi: 10.1016/j.bmc.2021.116185. Epub 2021 May 1. Bioorg Med Chem. 2021. PMID: 33965842
-
Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer.Eur J Med Chem. 2021 Dec 15;226:113870. doi: 10.1016/j.ejmech.2021.113870. Epub 2021 Sep 25. Eur J Med Chem. 2021. PMID: 34610548
-
Synthesis and structure-activity relationships of novel hybrid ferrocenyl compounds based on a bicyclic core skeleton for breast cancer therapy.Bioorg Med Chem. 2016 Jul 1;24(13):3062-3074. doi: 10.1016/j.bmc.2016.05.019. Epub 2016 May 18. Bioorg Med Chem. 2016. PMID: 27240467
-
Selective Histone Deacetylase Inhibitors with Anticancer Activity.Curr Top Med Chem. 2016;16(4):415-26. doi: 10.2174/1568026615666150813145629. Curr Top Med Chem. 2016. PMID: 26268343 Review.
-
Inhibitors of histone deacetylase as antitumor agents: A critical review.Bioorg Chem. 2016 Aug;67:18-42. doi: 10.1016/j.bioorg.2016.05.005. Epub 2016 May 17. Bioorg Chem. 2016. PMID: 27239721 Review.
Cited by
-
Norbornene and Related Structures as Scaffolds in the Search for New Cancer Treatments.Pharmaceuticals (Basel). 2022 Nov 25;15(12):1465. doi: 10.3390/ph15121465. Pharmaceuticals (Basel). 2022. PMID: 36558915 Free PMC article. Review.
-
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021).Signal Transduct Target Ther. 2022 Jun 9;7(1):181. doi: 10.1038/s41392-022-00999-9. Signal Transduct Target Ther. 2022. PMID: 35680848 Free PMC article. Review.
-
AIMP1 promotes multiple myeloma malignancy through interacting with ANP32A to mediate histone H3 acetylation.Cancer Commun (Lond). 2022 Nov;42(11):1185-1206. doi: 10.1002/cac2.12356. Epub 2022 Aug 30. Cancer Commun (Lond). 2022. PMID: 36042007 Free PMC article.
-
Epigenetic polypharmacology: from combination therapy to multitargeted drugs.Clin Epigenetics. 2016 Oct 12;8:105. doi: 10.1186/s13148-016-0271-9. eCollection 2016. Clin Epigenetics. 2016. PMID: 27752293 Free PMC article. Review.
-
Novel hybrid molecule overcomes the limited response of solid tumours to HDAC inhibitors via suppressing JAK1-STAT3-BCL2 signalling.Theranostics. 2018 Oct 5;8(18):4995-5011. doi: 10.7150/thno.26627. eCollection 2018. Theranostics. 2018. PMID: 30429882 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Medical
Miscellaneous